Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Role of Vitamin D Status in Optic Neuritis - An Update
MS and Related Diseases
S10 - (-)
004
The optic nerve is commonly targeted in demyelinating disease, providing a model for assessment of anti-inflammatory and neuroprotective therapies. Vitamin D is a known ameliorator of inflammatory activity. In-vitro evidence suggests it may also be neuroprotective, an examinable possibility using optic neuritis and OCT, in which degeneration is seen as early as 6 months.
Fifty patients with acute optic neuritis will undergo OCT testing to measure RFNL, macular volume and inter-eye RFNL difference, neurological examination and 25(OH)D testing at onset and month 6. Comparisons are made on OCT measures between vitamin D sufficient and insufficient patients at these times.
Currently 36 of 50 patients have been enrolled; 25 having completed the 6 month study. Twenty-four patients were vitamin D insufficient and 12 sufficient (mean 25(OH)D 60 nmol/L and 105 nmol/L respectively). Gender, age, disease category and steroid treatment did not differ between groups. Acutely, vitamin D insufficiency was associated with greater RFNL edema (136 vs 98 [micro]m, p=0.052) and macular volume (10.3 vs 9.8 mm3, p=0.032). At 6 months, mean inter-eye RFNL difference (IED) was 12 vs 2 [micro]m in vitamin D insufficient vs sufficient patients.
Results thus far show optic neuritis in the context of vitamin D insufficiency is associated with greater optic nerve structure edema acutely, and a greater degree of RFNL thinning (as measured by IED) at 6 months. These results suggest that vitamin D may be protective against both inflammatory and degenerative effects of demyelination.
Authors/Disclosures
Jodie Burton, MD, FÂ鶹´«Ã½Ó³»­
PRESENTER 		Dr. Burton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Burton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Burton has received personal compensation in the range of $0-$499 for serving as a Consultant for Horizon. The institution of Dr. Burton has received research support from Roy and Joan Allen Professorship for Sight. Dr. Burton has a non-compensated relationship as a Advisor with CADTH that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Alexion that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Horizon that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Burton has a non-compensated relationship as a Â鶹´«Ã½Ó³»­al Chair with EMD Serono that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
David C. Spencer, MD, FÂ鶹´«Ã½Ó³»­ Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuiticals. Dr. Spencer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace Inc. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various. The institution of Dr. Spencer has received research support from NIH. Dr. Spencer has received publishing royalties from a publication relating to health care. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Faculty in Teaching Course supported by unrestricted educational grants with Creative Â鶹´«Ã½Ó³»­ Concepts.
No disclosure on file
No disclosure on file
No disclosure on file
Fiona E. Costello, MD (Fiona Costello Professional Corporation) Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.